Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Scancell Holdings inks drug delivery technology deal

It has exercised an option on TriGrid, which was developed by Ichor Medical Systems
woman at a microscope
The new technology will be used in an upcoming cancer trial

Immunotherapy specialist Scancell Holdings PLC (LON:SCLP) has exercised an option to in-licence delivery technology for its lead drug candidate.

It has inked a deal with Ichor Medical Systems, which has developed the TriGrid 2.0 electroporation system.

READ: Scancell receives European patent protection for immunotherapy platform

TriGrid will now be used in harness with Scancell's SCIB1 vaccine, a melanoma treatment.

Specifically, it will be deployed in an upcoming Phase II clinical trial in which the Scancell drug candidate is being deployed alongside a checkpoint inhibitor.

Vital component 

Chief executive Cliff Holloway said: "Ichor's proprietary TriGrid electroporation delivery system is a vital component for the delivery of our SCIB1 vaccine and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, which is expected to commence later this year.

“The exercise of this commercial option is a further key milestone in bringing this important new treatment to the market."

The company said an option fee will be paid. Ichor will receive further cash once certain developmental milestones are passed.

Scancell has also agreed an extension for the exercise of share options granted to Ichor as part of the initial deal.

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use